Previous studies have demonstrated that patients with CSPC with low PTEN expression have lower response rates to androgen deprivation therapy, whereas the loss of RB1 gene expression is associated with an increased risk of developing castration‐resistant PCa along with worse overall survival.22, 23, 24, 25. The gene discussed is RB1; the disease is posterior cortical atrophy.